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Abstract
Background: We have investigated the possibility and feasibility of producing the HPV-11 L1
major capsid protein in transgenic Arabidopsis thaliana ecotype Columbia and Nicotiana tabacum cv.
Xanthi as potential sources for an inexpensive subunit vaccine.
Results: Transformation of plants was only achieved with the HPV-11 L1 gene with the C-terminal
nuclear localization signal (NLS-) encoding region removed, and not with the full-length gene. The
HPV-11 L1 NLS- gene was stably integrated and inherited through several generations of transgenic
plants. Plant-derived HPV-11 L1 protein was capable of assembling into virus-like particles (VLPs),
although resulting particles displayed a pleomorphic phenotype. Neutralising monoclonal
antibodies binding both surface-linear and conformation-specific epitopes bound the A. thaliana-
derived particles and – to a lesser degree – the N. tabacum-derived particles, suggesting that plant-
derived and insect cell-derived VLPs displayed similar antigenic properties. Yields of up to 12 μg/g
of HPV-11 L1 NLS- protein were harvested from transgenic A. thaliana plants, and 2 μg/g from N.
tabacum plants – a significant increase over previous efforts. Immunization of New Zealand white
rabbits with ~50 μg of plant-derived HPV-11 L1 NLS- protein induced an antibody response that
predominantly recognized insect cell-produced HPV-11 L1 NLS- and not NLS+ VLPs. Evaluation of
the same sera concluded that none of them were able to neutralise pseudovirion in vitro.
Conclusion: We expressed the wild-type HPV-11 L1 NLS- gene in two different plant species and
increased yields of HPV-11 L1 protein by between 500 and 1000-fold compared to previous
reports. Inoculation of rabbits with extracts from both plant types resulted in a weak immune
response, and antisera neither reacted with native HPV-11 L1 VLPs, nor did they neutralise HPV-
11 pseudovirion infectivity. This has important and potentially negative implications for the
production of HPV-11 vaccines in plants.
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Background
Papillomaviruses are small species- and tissue specific
double-stranded DNA tumour viruses, classified in the
taxonomic family Papillomaviridae. High-risk genital HPVs
types 16, 18, 33 and 58 are the leading cause of cervical
cancer [1], and low-risk genital HPVs such as the related
types 6 and 11 cause benign epithelial papillomas or
warts. HPV-11 is recognised as one of the most prevalent
anogenital papillomaviruses and is the main causal agent
of benign genital warts (condyloma acuminata) and
laryngeal condylomas. Furthermore, HPV-11 DNA has
also been found to be associated with various other
mucosal surfaces [2-5].
Given a HPV-11 prevalence rate of 5–12% in normal
women [6-8], a serious recent concern is the impact of
increasing human immunodeficiency virus (HIV) infec-
tion rates, and the associated immunosuppression of HIV-
positive individuals, on HPV-6 or 11 coinfections. HPV-
associated disease is the most common coinfection and
comorbidity in immunosuppressed individuals [9]. HPV
infections are more readily detected in HIV-seropositive
women, are more persistent, more severe and more diffi-
cult to treat than HPV infections in HIV-seronegative
women, and recur more frequently. Silverberg et al. [10]
have found the prevalence of HPV-6 and 11 to be up to
5.6 times higher in HIV-seropositive women, thereby
increasing the prevalence of genital warts by a factor of
3.2. The associated morbidity and negative effects on
quality of life are a major problem among HIV-infected
women (L Denny, pers comm). Thus, although HPVs 6
and 11 are not cancer-causing, infections can be disfigur-
ing and cause severe discomfort. The complications of
HPV-11 coinfection in HIV-seropositive individuals
necessitate the urgent development of a safe, efficacious
and inexpensive vaccine against HPV-11.
While efforts to develop HPV vaccines have largely con-
centrated on the cervical cancer-causing HPV-16, HPV-11
has also received widespread attention. Extremely high
healthcare costs are associated with management of non-
cancerous HPV-6/11 disease, and inclusion of HPV-6 and
11 in a vaccine might be advantageous [11]. Phase I clini-
cal trials have proven that HPV-11 L1 virus-like particle
(VLP) vaccines are safe [12]. Merck has developed a quad-
rivalent HPV vaccine, Gardasil™, which includes HPV-6,
11, 16 and 18 and is produced in yeast: two large Phase III
trials have been completed and it was licensed for use in
the United States in June 2006 [13]. A modelling study
[14] predicted significant improvements in the quality of
life and prevention of cancer upon vaccination of young
girls with an HPV vaccine that was only 75% efficacious.
However, the Merck HPV vaccine will cost US$360 for 3
doses/person – an amount that is higher than the annual
per capita health expenditure of many third-world
nations. Therefore, other strategies for the production of
stable, cheaper HPV vaccines are more immediately
appropriate for these constituencies.
A strategy for the large-scale production of inexpensive
HPV vaccines is production in plants: this could be
between 10 and 50 times cheaper than its production in
fermentation systems. Delivery of these by the oral or
"needle-free" route is ideally suited to the background set-
ting of vaccination campaigns in many developing coun-
tries [15]. We and others have shown that plant-expressed
HPV-11 L1 and HPV-16 L1 proteins assemble into anti-
genically-appropriate capsomers and VLPs that are highly
immunogenic upon parenteral and/or oral delivery to ani-
mals [16-20]. HPV-11 VLPs were expressed in potato;
however, yields were very low and oral administration of
tuber material was only weakly immunogenic [19]. We
have also shown that a plant-produced cottontail rabbit
papillomavirus (CRPV) capsomer vaccine protected rab-
bits against the formation of CRPV-induced papillomas
[21], which so far is the only proof of concept for a plant-
produced PV L1 protein vaccine.
This study aimed to develop a plant-derived L1 protein
subunit vaccine against HPV-11 in a plant host from
which it could be easily purified at reasonable yield, in
order to formulate a potentially cheap vaccine that could
help prevent HPV-11 infection in developing countries.
Through Agrobacterium tumefaciens-mediated transforma-
tion, we genetically manipulated Arabidopsis thaliana and
Nicotiana tabacum, to express the HPV-11 L1 gene. Com-
parative studies on the expression of the gene were per-
formed on both expression systems. Products were
characterised antigenically using monoclonal antibodies
and used to immunise rabbits, in parallel with insect cell-
produced antigens.
Results
Genetic analysis of transgenic plants
Despite several attempts to transform A. thaliana and N.
tabacum plants with the HPV-11 L1 and HPV-11 L1 NLS-
genes, only plants containing the HPV-11 L1 NLS- gene
could be regenerated. Attempts to introduce the full-
length HPV-11 L1 gene failed in both plant systems. PCR
screening of putative HPV-11 L1 NLS- transgenic A. thal-
iana first generation (T1) and N. tabacum regenerated gen-
eration (R0) plants, using primer pair 4 as listed in Table
1, showed that 8/20 A. thaliana T1 generation and 4/15 N.
tabacum R0 lines were positive for the gene.
Inheritance of the transgene was established by self-polli-
nating T1 plants and screening seeds on selective media.
Random PCR screening of plant lines up to the T6 genera-
tion for A. thaliana and T3 generation for N. tabacumBMC Biotechnology 2007, 7:56 http://www.biomedcentral.com/1472-6750/7/56
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showed that the gene was stably integrated and success-
fully inherited (Figure 1A and 1B).
To determine transcription of the integrated HPV-11 L1
NLS- gene, total RNA of successive generations of A. thal-
iana  and  N. tabacum plants was analysed by RT-PCR.
Amplification of a 303 bp product indicated the presence
of the HPV-11 L1 NLS-transcript and we determined that
the HPV-11 L1 NLS- mRNA was present in PCR-positive
transgenic plants in all generations (Figure 1C and 1D).
Analysis of plant-derived HPV-11 L1 NLS- protein
The final product resulting from homogenization, filtra-
tion and centrifugation of transgenic leaf material was
analysed by standard techniques and showed that HPV-11
L1 NLS- protein was indeed present in the concentrated
plant protein extracts (Figures 2 and 3).
Monoclonal antibodies (Mabs) to HPV-6 (H6:C6, H6:E51
and H6:I2); HPV-11 (H11:B2 and H11:H3) and to HPV-
16 (H16:D9) displaying specific and cross-reactive prop-
erties (Table 2) were used in the ELISA to detect and char-
acterise the antigenicity of HPV-11 L1 NLS-  protein
derived from both plant hosts (Figure 2A and 2B). For A.
thaliana-derived HPV-11 L1 NLS- protein, T3 generation
plants from all 8 lines were harvested and pooled. Our ini-
tial interest was in determining whether or not the protein
was expressed at all in A. thaliana, rather than in selecting
high or low expressers. The limited biomass obtainable
from these plants necessitated the pooling of leaf material
from all transgenic lines. The resulting protein extract was
characterised with all the above listed Mabs. The results in
Figure 2A show that all Mabs bound to the A. thaliana-
derived L1-containing protein extract. Binding of HPV-11
neutralising conformation-specific Mabs H11:B2 and
H11:H3 to antigen in the plant protein extract was essen-
tially equivalent to the binding to the positive control,
suggesting that A. thaliana-derived HPV-11 L1 NLS- pro-
tein could potentially elicit a neutralising antibody
response once administered.
Further, Figure 2A shows evidence of binding of the HPV-
6/11 cross-reactive surface linear Mabs H6:C6, H6:E51
and H6 I2 to the protein extract: these Mabs bind intact
VLPs as well as denatured L1 protein. Although binding of
these Mabs was not of the same magnitude as to the pos-
itive control (Figure 2A), together these results suggest
that most of the A. thaliana-derived HPV-11 L1 NLS- pro-
tein is assembled similarly to insect cell-produced protein.
Analysis of the antigenic properties, of the N. tabacum-
derived HPV-11 L1 NLS- protein from all generations from
4 lines showed that the surface linear and HPV-11 neutral-
ising antibody H6:I2 bound best. Two other cross-reactive
Mabs (H6:C6 and H6:E51) also bound; however, binding
efficiencies of these surface exposed linear epitope-recog-
nizing and non-HPV-11-neutralising Mabs were signifi-
cantly lower (Figure 2B).
Conformation-specific and HPV-11 neutralising Mabs
H11:B2 and H11:H3, which only bind capsomers and
intact VLPs, did not react significantly with plant extracts,
suggesting that most of the N. tabacum-derived HPV-11 L1
NLS- protein exists in an unassembled state. The rather
weak detection of the HPV-11 L1 NLS- VLP spiked positive
control by MAb H16:D9 was anticipated, as it is not suit-
able for detecting intact VLPs (Figure 2B).
A similar assay on insect cell-derived HPV-11 VLPs diluted
in PBS instead of non-transgenic plant extract gave quali-
tatively identical results to those in Figures 2A and 2B
(result not shown), indicating that addition of plant sap
does not change the VLP antigenic properties.
Quantitation of the L1 protein
The amount of L1 protein in transgenic plant extracts was
measured by comparison to an ELISA-derived standard
curve for known concentrations of insect cell-derived
HPV-11 L1 NLS- protein. Non-transgenic plant protein
extract was initially spiked with insect cell-derived HPV-
11 L1 NLS- VLPs resulting in a known concentration of 0.4
Table 1: Primers used for the amplification of the HPV-11 L1 and L1 NLS- ORFs
Primer Pair Construct Primers
1 pHPL51 (502) Forward 5'- GGAATTCCGGAGGAATTTTTTACAGATGTGGCGGC -3'
Reverse 5'- GACGCCGTCGACTCCGGAACTGACACACATATATTAG -3'
2 pHPS51 (ΔC481) Forward 5'- GGAATTCCGGAGGAATTTTTTACAGATGTGGCGGC -3'
Reverse 5'- ACGCCGTCGACTCCGGATTATATACCTGTTACGAGCAGC -3'
3 pART27 L1 Forward 5'- ATGTGGCGGCCTAGCGAC -3'
Reverse 5'- TTACTTTTTGGTTTTGGTACGTTTTCG-3'
4 pART27 L1 NLS- Forward 5'- ATGTGGCGGCCTAGCGAC -3'
Reverse 5'- TTATATACCTGTACGAGCAGACG -3'
5 HPV-11 L1 NLS- internal Forward 5'- TGATACAGGCTTTGGTGC -3'
Reverse 5'- TGGCTCATTGGTGTCTTC -3'
GAATTC:EcoRI; TCCGGA:MroI, GTCGAC:SalI, ATG = start codon, TAA = stop codonBMC Biotechnology 2007, 7:56 http://www.biomedcentral.com/1472-6750/7/56
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μg per well (100 μl); O.D.405nm comparisons allowed cal-
culation of the total amount of L1 protein from transgenic
A. thaliana and N. tabacum extracts for which the total
plant weight and homogenisation buffer volume was
known. Overall yields of L1 protein harvested from A.
thaliana were calculated to range from between 3 and 12
μg/g, whereas N. tabacum plants yielded between 0.2 and
2.2 μg/g of fresh leaf material.
Electron microscopy
A. thaliana and N. tabacum protein extracts were immu-
notrapped onto grids using anti-HPV-11 L1 polyclonal
antiserum and stained with 2% uranyl acetate (Figures 3A
and 3B). A range of different particle sizes varying from 20
to 60 nm in diameter were observed in both protein
extracts. Furthermore, the presence of L1 protein was
detected by immunogold-labeling of the plant-derived
Genomic DNA analysis of transgenic plants Figure 1
Genomic DNA analysis of transgenic plants. (A) Analysis of individual transgenic A. thaliana lines of the T6 generation 
(A1-4 represent 4 plants of line A; B1-4 plants from line B etc.), indicating the presence of the HPV-11 L1 NLS- gene. (B) 
Screening of genomic DNA extracted from transgenic N. tabacum line X1 (T1 generation) plants for the presence of the HPV-
11 L1 NLS- gene. The majority of the individual plants are positive for the HPV-11 L1 NLS- gene, as is shown by a 1.5 kb PCR 
amplification product. Genomic DNA extracted from respective non-transgenic plants and HPV-11 L1 NLS- plasmid DNA rep-
resent the negative and positive controls respectively. (C) RT-PCR analysis of PCR positive transgenic A. thaliana plants from 
the T1, T2, T3 and T6 generations and (D) of individual T1, T2 and T3 generation N. tabacum plants from lines X1, Xi, and Xk. 
(for example: Xi 2.5 represents line Xi, T2 generation, plant number 5). Individual plants from the respective lines express the 
L1 NLS- gene as shown by the 303 bp amplification product. Total RNA extracted from respective non-transgenic plants repre-
sent the negative control.
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Detection of HPV-11 L1 protein in plant extracts using ELISA Figure 2
Detection of HPV-11 L1 protein in plant extracts using ELISA. (A) VLP characterisation by ELISA, utilising conforma-
tion-specific and linear MAbs, of HPV-11 L1 NLS- transgenic T3 generation A. thaliana protein extract from pooled lines and (B) 
N. tabacum protein extract from individual lines and generations. (for example: X1.2 represents line X1, T2 generation). Non-
transgenic A. thaliana or N. tabacum protein extract was used as negative control; the positive control consisted of non-trans-
genic protein extract spiked with 0.4 μg/well insect cell-derived HPV-11 L1 NLS- VLPs. Error bars represent the standard devi-
ation calculated from triplicate analysis of samples.
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extracts, thus reconfirming these observations (results not
shown).
Insect cell-produced VLPs in non-transgenic plant extract
immunotrapped using Mab H11:H3 represent the posi-
tive control (Figure 3C); negative controls were protein
extracts derived from non-transgenic A. thaliana (not
shown) and N. tabacum (Figure 3D): these showed no
HPV-like or any other particles upon examination.
Western blotting
Detection of HPV-11 L1 NLS- protein by western blot is
shown in Figure 4. While characteristic polypeptide bands
were detected in both plant extracts, the L1 protein
extracted from A. thaliana-derived L1 protein showed no
proteolysis: a ~55 kDa band in (A) matched that of the
positive control. In contrast, however protein from N. tab-
acum (B) was extensively proteolysed (~36 kDa) indicat-
ing that protease activities differ markedly between the 2
plant systems. HPV-11 L1 NLS-  in insect cell lysate
detected with H6:C6 (shown in C as Insect cell (IC)) was
cleaved twice, resulting in 3 products: one of these is ~36
kDa in size. Non-infected insect cell lysate was used as
negative control in C.
Animal immune response to plant-derived HPV-11 L1 
protein
Eight New Zealand white rabbits were immunized with
concentrated transgenic A. thaliana and N. tabacum pro-
tein extracts. Serum collected on days 1, 15, 28, 42, 56 and
70 was analysed for anti-HPV-11 L1 reactive antibodies by
ELISA and results are shown in Figure 5. Rabbits #11 and
#12 were immunised with T3 generation transgenic A.
thaliana-derived L1 protein extract calculated to contain
between 21 μg and 43 μg.
A distinct difference was noted in the immune responses
of these 2 rabbits: serum from rabbit #11 reacted well with
insect cell-produced NLS- VLPs (Figure 5), while rabbit
#12 showed no significant antibody response and can
hence be classified as a non-responder.
Rabbits #13 – #18 were immunised with N. tabacum-
derived protein extract: two rabbits per group were immu-
nised with N. tabacum protein extract from T1 generation
transgenic lines X1, Xh and Xi respectively. According to
the range of protein yield calculated per kg of fresh leaf
material, inoculum from line X1 contained between 13–
47 μg of L1 protein, whereas inocula from lines Xh and Xi
contained between 10–114 μg and 9.5–42 μg of L1 pro-
tein respectively.
Only sera from rabbits #14 and #17 reacted with HPV-11
L1 NLS- VLPs (Figure 5). This did not correlate with inoc-
ulum dose, as responder #14 received 13–47 μg, non-
responders #15 and #16 received 10–114 μg, and
responder #17 received 9.5–42 μg. Antisera from #14
reacted 3-fold stronger in comparison to the prebleed and
sera from #17 showed the highest response with antise-
rum reacting 7-fold stronger in comparison to prebleed
antiserum.
The most interesting result was obtained by evaluating
serum reactivities in ELISA against insect cell-produced
HPV-11 L1 NLS+ VLPs. Serum from rabbits inoculated
with A. thaliana-derived L1 protein extract failed to react,
whereas sera from rabbits#16 and #17 immunised with
N. tabacum-derived L1 protein appeared to weakly bind
this antigen, as indicated by rising absorbances of succes-
sive bleeds about two fold higher than the prebleed level
(results not shown). This lack of recognition of the HPV-
11 L1 NLS+ VLPs is of great concern because these VLPs
most closely resemble the actual virus: the implications of
this will be discussed later.
Electron microscopy of plant extracts Figure 3
Electron microscopy of plant extracts. (A) Electron 
micrograph of T3 generation A. thaliana-derived HPV-11 L1 
NLS- VLPs. (B) Electron micrograph of N. tabacum-derived 
HPV-11 L1 NLS- VLPs. Particles were immunotrapped using 
polyclonal antiserum at a dilution of 1:50 and on average 
range from 30 to 60 nm in diameter. (C) The positive con-
trol shows H11;H3 immunotrapped insect cell-derived HPV-
11 L1 NLS- VLPs, whereas immunotrapped non-transgenic 
plant protein extract is represented in D.BMC Biotechnology 2007, 7:56 http://www.biomedcentral.com/1472-6750/7/56
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To further investigate this, Day 56 antisera were tested
against denatured and non-denatured insect cell-derived
HPV-11 L1 NLS+ and NLS- VLPs by ELISA. The results
shown in Figure 6 essentially reconfirm those presented in
Figure 5. With the exception of rabbit #11, the antisera
from all remaining rabbits immunized with either plant-
derived protein extract reacted predominantly with non-
denatured insect cell-derived HPV-11 L1 NLS- VLPs, and
not with denatured protein from either type of VLPs. This
was confirmed by western blots of the insect cell-derived
NLS+ and NLS- protein. While very strong reactions were
seen with baculovirus and Sf21 cell proteins in both preb-
leed and last bleed sera, neither L1 protein was detected
(data not shown). This suggested that the predominant
antibody response was most probably not targeted against
any linear epitopes.
Pseudovirion neutralisation assays
All rabbit sera taken on days 1 and 56 were tested for their
capacity to neutralise HPV-11 pseudovirions. Serum sam-
ple dilutions ranging from 1:50 to 1:12150 were incu-
bated together with HPV-11 L1 pseudovirions before
Table 2: MAbs used for the detection and characterisation of the HPV-11 L1 NLS- protein
Monoclonal antibody Isotype Neutralisation Nature of Epitope Cross-reactivity References
H11:B2 IgG2b Yes (HPV-11) conformation-specific Yes (HPV-6 & 11) [13] [34] [35] [36]
H11:H3 IgG2b Yes (HPV-11) conformation-specific No
H6:C6 IgG2a No (HPV-11) linear (surface) Yes (HPV-6 & 11)
H6:E51 IgG1 No (HPV-11) linear (surface) Yes (HPV-6 & 11 & 18)
H6:I2 IgM Yes (HPV-11) linear (surface) Yes (HPV-6 & 11)
H16:D9 IgG1 No (HPV-11) linear (surface) Yes (HPV-11 & 16)
Western blot analysis of plant extracts Figure 4
Western blot analysis of plant extracts. (A) Western blot analysis of TCA-precipitated A. thaliana protein extract 
detected with H6:E51. HPV-11 L1 NLS- protein is present in both protein extracts from primary bolts and complete plants. M 
= MW marker; B = bolts; Pl = plants. (B) Western blot analysis of TCA precipitated N. tabacum protein extract detected with 
H6:I2. The HPV-11 L1 NLS- protein is present in all generations of the N. tabacum transgenic lines and is ~36 kDa in size. (-) 
represents the TCA precipitated non-transgenic control. The positive controls (+) and (+)* are insect cell-derived CsCl-puri-
fied HPV-11 L1 (NLS+) and HPV-11 L1 NLS- VLPs, respectively. (C) Western blot analysis of non-concentrated, non-purified 
HPV-11 L1 NLS- VLPs in insect cell lysate detected with H6:C6 (IC). Non-infected insect cell lysate was used as negative con-
trol (-) in C.
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being assayed. One of two internal controls was serum
from rabbit #19 (not previously shown), which was inoc-
ulated with insect cell-derived HPV-11 L1 NLS+ VLPs.
Dilutions of the conformation-specific and neutralising
MAb H11:H3 were the second positive control.
No specific neutralising capacity was observed for any pre-
bleed serum. However, while rabbit #19 serum (internal
positive control; anti-insect cell-produced L1) neutralised
the pseudovirion at the highest dilution tested (1:12150),
and the known conformation-specific and neutralising
MAb H11:H3 worked to a dilution of 1:106, none of the
post-inoculation day 56 sera were neutralising, even at the
lowest dilution of 1:50.
Taken together, these serological results indicate that
plant-derived HPV-11 L1 NLS- VLPs are modified to some
extent, yet still retain certain overall virion morphological
features as seen by electron microscopy. Immunisation of
animals, however, results in an antibody response that is
not capable of recognizing or neutralising HPV-11 L1
NLS+ VLPs, the closest counterpart to the actual virus.
Discussion
The focus of this study was on the expression of a native
HPV-11 L1 gene, as full-length and NLS- constructs, in
transgenic A. thaliana and N. tabacum, with the overall aim
of gaining some insight as to the feasibility of developing
a plant-derived vaccine against HPV type 11. This is
against a background of the release in 2006 of the
GARDASIL™ yeast-derived quadrivalent vaccine against
HPV types 6, 11, 16 and 18 by Merck: this vaccine has
already shown 100% effectiveness in protecting from
infection. However, the high cost of one course of this vac-
cine (3 doses; US$360) means that it will not prevent the
continuous spread of the virus-associated disease in the
foreseeable future, because it will remain largely non-
affordable to people in disadvantaged regions of the
globe.
Here we report on the successful transformation of both
A. thaliana and N. tabacum with the HPV-11 L1 gene miss-
ing the C-terminal nuclear localisation signal (NLS). This
increases the number of plant systems used for the suc-
cessful expression of HPV L1 proteins to include not only
Immunogenicity of plant extracts Figure 5
Immunogenicity of plant extracts. Analysis of serum from New Zealand white rabbits #11 and #12 immunized with A. 
thaliana-derived HPV-11 L1 NLS- VLPs and rabbits #13 to #18 immunized with N. tabacum-derived HPV-11 L1 NLS- VLPs. Rab-
bits were immunized on days 1, 28 and 56 and serum from days 1, 15, 28, 42, 56 and 70 post injection was tested by ELISA in 
wells coated with 0.4 μg insect cell-derived HPV-11 L1 NLS- VLPs. Data from rabbit #12 is incomplete as it had to be eutha-
nized due to growth of an abscess on the neck. Error bars represent the standard deviation calculated from triplicate analysis 
of samples.
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tobacco and potato, but now also Arabidopsis. Overall, our
tobacco lines yielded ~2 μg of L1 protein per g of fresh leaf
material, whereas up to 12 μg/g of L1 protein could be
extracted from whole Arabidopsis plants. Our group has
previously expressed unmodified CRPV L1 and HPV-16
L1 genes in transgenic tobacco to levels of 1 μg/g and 4 ng/
g of plant tissue respectively [21,17], and HPV-16 L1 via a
tobamovirus vector in N. benthamiana to ~40 ng/g [18].
Biemelt et al. [16] expressed a human codon-optimised
HPV-16 L1 gene in tobacco at a level of ~0.5% of the total
soluble protein content (TSP), and in potato to about
0.2% TSP or ~12 μg/g of tuber. Warzecha et al. [19]
expressed a plant codon-optimised HPV-11 L1 NLS- gene
in potato and reported extracting up to ~23 ng/g of fresh
tuber. The HPV-16 L1 levels of expression have since been
far surpassed by Maclean et al. [20]; this work reports a
500 – 1000 fold increase in yield compared to previous
reported expression of HPV-11 L1 [19].
We found that in planta expression of the wild-type HPV-
11 L1  gene presented great difficulties and that it was
effectively impossible to transform either one of our host
plants. Similar observations were made by Warzecha et al.
in 2003 [19] and despite their use of a plant codon-opti-
mised HPV-11 L1 NLS+ gene, the number of putative
transgenic plant lines remained low. The low number of
confirmed HPV-11 L1 NLS- transgenic plant lines in this
study reiterates the observation that integration and/or
expression of the HPV-11 L1 gene (full-length vs trun-
cated/wild-type vs codon-optimised) is generally not well
tolerated in plants.
This stands in direct contrast to results obtained with the
HPV-16 L1 gene, where expression of full-length L1 in
either native (Varsani et al., 2003d) or human codon-opti-
mised forms [16,20] was readily achieved. The latter stud-
ies concluded that the human codon-optimised HPV-16
L1 gene expressed better in plants than the plant codon-
optimised or wild-type genes. Although HPV-11 and 16
L1 genes differ significantly, their L1 proteins are func-
tionally very similar. Thus, the reasons for the difference
in transformability remain obscure. It is also interesting in
light of the HPV-16 results that our native HPV-11 L1 gene
expressed so much better than the plant codon-optimised
candidate of Warzecha et al. [19]: this indicates that
expression of HPV L1 genes is best assessed empirically,
rather than by assuming that gene optimisation according
to plant codon usage will automatically improve expres-
sion.
The NLS of the HPV-11 L1 gene is not required for correct
VLP assembly [22]. Resulting particles remain morpho-
logically and antigenically identical to native virions
despite removal of 21 aa from the C-terminus [19]. There-
fore the truncated HPV-11 L1 protein should still be usa-
ble as a vaccine and given the difficult and unpredictable
in planta expression levels achieved with a spectrum of
HPV L1 genes, we had decided to focus on maximizing the
expression of the wild-type HPV-11 L1 NLS- gene in our
two expression hosts.
We were able to show successful transgene integration as
well as stable inheritance in consecutive generations (Fig-
ure 1A and 1B). Transcription of the gene was investigated
using RT-PCR: active transcription was shown throughout
successive generations of both plant systems (Figure 1C
and 1D). One possible shortcoming of this approach
however, given that Biemelt et al. [16] and Warzecha et al.
[19] found by northern blot that their respective L1
mRNAs were somewhat degraded, was that such degrada-
tion was not detectable in our system.
We further investigated if the L1 monomers formed VLPs.
We found that expression of the HPV-11 L1 NLS- gene via
recombinant baculovirus in Sf21 cells resulted in a range
of different sized particles that did not resemble the clas-
sical shape (Figure 3C). Furthermore, particles seen in
both  A. thaliana and  N. tabacum protein extracts had
shown the same pleomorphy, ranging from 20 to 60 nm
in diameter (Figure 3A and 3B). Li et al. [23], previously
found that removal of 11 carboxyl-terminal amino acids
still allowed for VLP assembly, but that particles were less
uniform than those resulting from expression of the full-
length L1 gene. Warzecha et al. [19] found particles in
HPV-11 L1-transformed potato but did not report pleo-
morphy as seen here.
Given several observations of differences between plant-
and insect cell-produced HPV-11 L1 proteins, we deter-
mined whether proteolytic degradation occurred for
insect cell-derived L1 protein. Crude insect cell lysate con-
taining HPV-11 L1 NLS- protein was left standing at 4°C
for several hours before being examined by western blot:
3 distinct L1 proteolytic products were seen (Figure 4C),
of ~53, ~45 and ~36 kDa relative to the purified 55 kDa
positive control. Li et al. [23] had reported that the HPV-
11 L1 protein is susceptible to trypsin digestion, resulting
in two distinctive products of ~42 and ~48 kDa in size.
Our western blot analyses of insect cell and plant-derived
HPV-11 L1 NLS- proteins showed that the N. tabacum-
expressed HPV-11 L1 NLS- protein is subject to severe deg-
radation: digestion by a presumably trypsin-like protease
resulted in a product of ~36 kDa (Figure 4B). Unlike pro-
teolysis in the crude insect cell lysate (Figure 4C), no inter-
mediate species were observed in the N. tabacum protein
extract, suggesting that despite the addition of complete
protease inhibitor throughout the extraction process,
complete proteolysis of the L1 protein occurred over time.BMC Biotechnology 2007, 7:56 http://www.biomedcentral.com/1472-6750/7/56
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Little is known about the properties of L1 proteins that
have undergone this degree of proteolysis. Assuming they
are incapable of assembly into capsids or of exhibiting
virus-specific conformational epitopes could partially
explain the ELISA results for tobacco-derived proteins
shown in Figure 2B. However, particles were observed by
electron microscopy (Figure 3B). It could be that VLP
assembly occurred during the concentration process,
rather than in planta; and then only of a subset of L1 mon-
omers that had not yet been completely proteolysed.
Although analysis of the A. thaliana protein extract was
anticipated to yield similar results, surprisingly no degra-
dation was observed in the extracted HPV-11 L1NLS- pro-
tein (Figure 4A). Furthermore, no significant alterations to
the N. tabacum-derived HPV-16, the potato-derived HPV-
11 L1 protein or of plant-derived CRPV L1 had been
reported in previous studies [16-19][21]. However, ours
was the only study with HPV-11 L1 expressed in tobacco
– and given the already proven unpredictability of L1
expression in plants, perhaps this is just more proof that
empiricism is the only way to approach this subject.
The phenomenon of the HPV-11 L1 NLS- proteins being
severely degraded in N. tabacum plants but not in A. thal-
iana  is interesting, and would undoubtedly impact on
their vaccine potential. Given the evidence of proteolysis
Antigenic specificity of immune sera Figure 6
Antigenic specificity of immune sera. Analysis of Day 56 antiserum from individual rabbits immunized with HPV-11 L1 
NLS- plant protein extract. Sera were tested against equal concentrations of denatured and non-denatured insect cell-derived 
HPV-11 L1 NLS+ and NLS- VLPs at a concentration of 0.4 μg/well. Error bars represent the standard deviation calculated from 
triplicate analysis of samples. Insect cell-derived VLPs were denatured at 100°C for 10 min. Rabbits #11 and #12 were immu-
nized with A. thaliana-derived HPV-11 L1 NLS- antigen. Rabbits #13 and #14, #15 and #16, and #17 and #18 were inoculated 
with N. tabacum-derived protein extract from T1 generation transgenic plant lines X1, Xh and Xi respectively.
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and particle pleomorphism, we investigated whether the
antigenic properties of the plant-derived VLPs had been
retained. It has been reported that removal of 86 aa from
the HPV-11 L1 C-terminal end resulted in the formation
of pentameric capsomers that were no longer able to
establish inter-capsomeric contacts: however, the MAb
H11:H3 capsid-neutralising domain was entirely con-
tained within pentameric L1 capsomers and interpen-
tamer associations were not required for the induction of
virus-neutralising antibodies [24]. However, tobacco-pro-
duced VLPs did not bind the conformation-specific MAb
H11:H3 (Figure 2B). Another conformation-specific and
neutralising MAb (H11:B2) also failed to bind the tobacco
plant-derived protein. This is similar to the case of Chen
et al. [25], where the formation of VLPs from severely
truncated COPV L1 protein did not necessarily preserve
conformation-specific epitopes on the surface of the cap-
sid. In contrast, all Mabs, including the conformation-spe-
cific and neutralising Mabs, were capable of binding to the
non-proteolysed  A. thaliana-produced HPV-11 L1 NLS-
(Figure 2A).
It is of utmost importance to establish whether any poten-
tial viral vaccine is capable of eliciting an appropriate anti-
body response. Accordingly, we evaluated the ability of
the plant extracts to induce an antibody response in rab-
bits. With perhaps the exception of serum collected from
rabbit #17 all immune sera reacted with insect cell-
derived NLS- VLPs (Figures 5 and 6), and not with NLS+
VLPs. This was unexpected, given that especially the A.
thaliana-derived L1 protein reacted with Mabs specific for
conformation-dependent epitopes. Additionally, serum
collected on day 56 reacted exclusively with non-dena-
tured insect cell-derived NLS-  VLPs (Figure 6). Taken
together, these results present a major problem – both for
interpretation and potentially for the prospect of HPV-11
plant-produced vaccines. We note that Warzecha et al.
[19] found that their plant-derived material reacted with
appropriate antibodies, but that no reaction could be
shown by sera from orally immunized mice with insect
cell-derived VLPs – presumably NLS+ – unless the mice
had been orally boosted with those VLPs. In contrast, it
has been shown that injection of plant-produced HPV-16
and CRPV L1 elicited antibodies reactive with native VLPs
produced in insect cells [16,17,20,21]. Thus, this phe-
nomenon is apparently limited to the HPV-11 L1 NLS-
protein.
Of more concern to the prospects of a plant-produced
HPV-11 vaccine was the fact that none of the sera collected
on day 56 could neutralise HPV-11 pseudovirions. While
we have previously shown that rabbits immunized with
plant-derived CRPV L1 protein were protected against live
CRPV challenge in the absence of detectable neutralising
antibodies [21], this is the only such result to our knowl-
edge, and it is generally taken as given that the primary
correlate of protection against papillomavirus infection is
the presence of neutralising antibodies. We note too that
Maclean et al. [20] were able to show pseudovirion neu-
tralisation after immunisation of mice with plant-derived
HPV-16 L1 VLPs.
We suggest that an immune response to plant-derived
HPV-11 L1 NLS- is elicited mainly against an immunodo-
minant epitope that appears to be surface exposed in
VLPs. The nature of the structural changes that occur
within the capsid that allow for recognition of this
epitope, which is otherwise not surface exposed on the
actual HPV-11 virion, need further investigation. Never-
theless, the lack of recognition by immune sera of the
HPV-11 L1 NLS+  VLPs, the closest counterpart to the
actual virus, implies that antibodies generated from injec-
tion of this particular plant-derived HPV-11 L1 NLS- pro-
tein will not be able to prevent infection and disease,
which completely negates their potential use for prophy-
lactic vaccination.
However, we feel it would be a mistake to neglect further
work on the development of an HPV-11 vaccine in plants.
With the possibility of using a plant-derived HPV-11 vac-
cine as cost-effective vaccine boosters, the goal would be
to make it work effectively. It might be possible to do this
by engineering the protein in a different way, or making
HPV-11:HPV-16 hybrid L1s, for example. It will also be
interesting to investigate if with new second and third
generation plant expression vectors, expression of full
length native HPV-11 L1 protein can be achieved, and if
alternative codon optimisation or expression strategies
will have an impact on expression levels, conformation
and immunogenicity of this product.
Conclusion
In summary, we expressed the HPV 11 L1 NLS- gene in two
different plants, upon which we found that in A. thaliana
VLPs were formed. These particles were recognised by con-
formation-specific antibodies and when analysed by west-
ern blot, a 55 kDa protein was observed. In contrast,
however, HPV 11 L1 NLS- VLPs from N. tabacum were not
recognized by the same conformation-specific antibodies
even though VLPs were observed by EM. The protein
seemed to be partially degraded as shown by the presence
of a 36 kDa band in western blots. This work also showed
that yields of HPV-11 L1 protein in plants could be
increased by between 500 and 1000-fold compared to the
only previous report [19], despite the use of a native HPV
L1  gene rather than a plant codon-optimised version.
Inoculation of rabbits with plant extract from both types
of plants resulted in a weak immune response, and antis-
era did not react with native HPV-11 L1 VLPs, nor did they
neutralise HPV-11 pseudovirion infectivity. As HPV-11 L1BMC Biotechnology 2007, 7:56 http://www.biomedcentral.com/1472-6750/7/56
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NLS+ VLPs are the closest counterpart to the actual virus it
follows that antibodies generated from injection of our
plant-derived HPV-11 L1 NLS- protein will not be able to
prevent infection and disease. This has serious implica-
tions for the further development of plant-derived HPV-
11 vaccines.
Methods
Cloning of HPV-11 L1 into Agrobacterium tumefaciens
Full-length and truncated HPV-11 DNA fragments derived
from the L1 ORF were amplified from a HPV-11 DNA-
positive biopsy sample clone (A-L Williamson, University
of Cape Town) using primer pairs 1 and 2 respectively
(Table 1), cloned into the pMOSBLUE vector and
sequenced. Primer pair 2 was used to exclude the bipartite
C-terminal nuclear localisation signal (NLS; KRpavskp-
stapKRKRTKTKK) spanning aa 482 – 502. PCR was per-
formed using standard cycling conditions, with an
annealing temperature of 55°C. A silent mutation at posi-
tion 257 (C to T) was found, otherwise this HPV-11 L1
sequence does not differ from the prototype HPV-11 L1
sequence (GenBank accession number M 14119).
The HPV-11 L1 and HPV-11 L1 NLS- ORFs were excised
and cloned into pUC19 (EcoRI/SalI), and thereafter direc-
tionally cloned (EcoRI/HindIII) into plasmid pART7: this
placed the L1 genes downstream of the CaMV35S pro-
moter and upstream of the octopine synthase gene termi-
nator (ocs 3'). This cassette was excised (NotI) and cloned
into the A. tumefaciens binary vector pART27 [26]. A. tume-
faciens C58C1RifR competent cells were transformed with
HPV-11 L1/HPV-11 L1 NLS- pART27 DNA using a freeze-
thaw method [27]. Selection was done on media contain-
ing kanamycin (40 μg/ml) and rifampicin (100 μg/ml) at
30°C. Transformants were screened by PCR as described
above, using primer pairs 3 (HPV-11 L1) and 4 (HPV-11
L1 NLS-) (Table 1).
Synthesis of HPV-11 L1 protein in insect cells
The full-length and NLS- L1 genes described above were
cloned, using standard techniques, into the pFastBac vec-
tor (Invitrogen™), transformed into Escherichia coli
DH10BAC competent cells, and recombinant baculovirus
was generated by transfection of the bacmid DNA into
Sf21 cells (Manufacturer's protocol, Invitrogen™,
Carlsbad, California). HPV-11 L1 protein was produced in
Sf21 cells and virus-like particles (VLPs) were prepared as
described [17].
Transformation of Arabidopsis thaliana
A. thaliana ecotype Columbia plants were transformed
with  A. tumefaciens constructs (HPV-11 L1/HPV-11  L1
NLS-) by a simplified transformation protocol [28]. Pri-
mary bolts were cut off to induce proliferation of second-
ary bolts, then after 4 days plants were dipped in A.
tumefaciens  cultures containing either pART27 L1  or
pART27 L1 NLS-. A. tumefaciens cultures were harvested
after 2 days and resuspended to OD600 = 0.8 in phosphate
buffered saline (PBS, 1.47 mM KH2PO4, 10 mM
Na2HPO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4) contain-
ing 5% (w/v) sucrose and surfactant Silwet-77 at a concen-
tration of 0.03% (v/v). Dipped plants were grown at 16/8
hr day/night photoperiod until seeds were harvested. To
determine the transformation efficiency and to screen for
transformed plants, dry seeds were sterilised in 10%
bleach, washed 3 times in water and plated on plant nutri-
ent sucrose medium (PNS) containing kanamycin (250
μg/ml). Germination was allowed to take place under a
16/8 hr photoperiod, at 25°C and 80% relative humidity.
Seedlings were left on PNS media until complete develop-
ment of a mature 4th leaf, before being transplanted to
soil.
Transformation of Nicotiana tabacum
The transformation protocol of Horsch et al. [29] was used
for the generation of transgenic N. tabacum plants. Steri-
lised leaf discs (±1 cm2) were dipped into a 48 hr A. tume-
faciens culture carrying either the HPV-11 L1 or HPV-11 L1
NLS- construct. Squares were transferred to non-selective
co-cultivation media [30] for 72 hrs, follwed by MS regen-
eration/shooting media with kanamycin (300 μg/ml) and
cefotaxim (250 μg/ml) until small shoots appeared from
the calli. Shoots with 1 to 2 leaves were transferred to MS
root-inducing media with kanamycin (100 μg/ml). Once
roots were formed, plants were transferred to soil and
grown to maturity with a 16/8 hr photoperiod at 25°C
and 80% relative humidity. Flowering plants were self-
pollinated and dry seeds screened on media containing
kanamycin (250 μg/ml) before putative transgenic seed-
lings were transferred to soil, once the 4th leaves had
grown to maturity.
Screening of plants for the HPV-11 L1 and L1 NLS- genes
Plant genomic DNA was extracted from putative trans-
genic and wild type A. thaliana and N. tabacum plants
using the Dellaporta method [31] and screened by PCR
for the HPV-11 L1  and HPV-11 L1 NLS- genes using
primer pairs 3 and 4 (Table 1).
Analysis of total RNA extracted from transgenic plants
Total RNA was extracted from fresh leaves using TRIzol™
reagent (Life Technologies). Detection of the L1 NLS-
mRNA was achieved by RT-PCR using the Access RT-PCR
system (Promega). Primer pair 5 (Table 1) was used to
amplify an internal 300 base pair fragment according to
the manufacture's instruction.
Processing and concentration of transgenic plant material
Entire A. thaliana plants and leaves from N. tabacum were
harvested and homogenised in 1:2 (w/v) cold 0.1 m phos-BMC Biotechnology 2007, 7:56 http://www.biomedcentral.com/1472-6750/7/56
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phate/0.5 m NaCl ph 7.4 high salt buffer (HSP buffer).
The homogenate was filtered through cheesecloth and
centrifuged at 6000 × g for 10 min. 10% (w/v) polyethyl-
ene glycol (PEG mw 8000) was added to the supernatant
before it was centrifuged at 6000 × g for 20 min. The pellet
was resuspended in 1/10th original volume HSP buffer
and centrifuged at 6000 × g for 20 min to remove further
debris; the remaining supernatant was centrifuged at
100.000 × g for 180 min. The final pellet was resuspended
in 1/10th of the previous volume of hsp buffer used.
Monoclonal antibody characterisation of plant-derived 
HPV-11 L1 protein
HPV-11 L1 NLS- protein-containing extracts derived from
A. thaliana and N. tabacum, together with non-transgenic
plant protein extracts, were characterised by ELISA using a
panel of Mabs to HPV-6, HPV-11 and HPV-16 [32], (Table
2). ELISA plates were coated with protein extracts for 1 hr
and then blocked in 5% non-fat milk in PBS for 1 hr.
Mabs (1:1000) were used to detect the plant-derived anti-
gen for 1 hr. Anti-mouse-alkaline phosphatase conjugated
secondary antibody (1:5000, Sigma) was allowed to bind
the primary antibody for 1 hr at 37°C. The secondary anti-
body was detected using p-nitrophenyl phosphate (pNPP,
Sigma) and the absorbance measured at 405 nm. All sam-
ples were analysed in triplicate to determine the mean
absorbance and calculate the respective standard devia-
tion.
Western blot analysis of plant-derived HPV-11 L1 protein
5% (v/v) trichloroacetic acid (TCA) was added to plant
protein extracts before being centrifuged at 8000 × g for 20
min at 4°C. The pellet was washed twice in 100% ace-
tone/20 mM HCl before the pellet was resuspended in 25
mM Tris, 2% SDS (1/5th original volume). Plant protein
extracts were denatured at 100°C for 10 min in SDS-PAGE
gel loading buffer, resolved on a 12% acrylamide gel and
transferred onto nitrocellulose membrane by semi-dry
electroblotting. L1 protein was detected with Mabs to
HPV-6 L1 (H6:C6 and H6:E51, Table 2) at dilutions of
1:1000 and then probed with goat anti-mouse-alkaline
phosphatase conjugated secondary antibody at 1:5000.
Colorimetric detection was performed with NBT/BCIP
tablets (Roche)
Electron microscopy of HPV-11 L1 protein
A. thaliana and  N. tabacum plant protein extracts and
insect cell-derived HPV-11 L1 protein were viewed either
directly or after immunotrapping onto carbon-coated
copper grids. Protein samples were directly adsorbed onto
grids as described [21] or immunotrapped with rabbit-
anti-HPV-11 L1 antiserum raised against insect cell-
derived HPV-11 L1 VLP (1/50) Grids were washed in H2O
and stained with 2% uranyl acetate.
Immunogold-labeling of plant-derived L1 protein
involved immunotrapping of L1 as described above,
probing grids with HPV-11 MAb H11:H3 (1:1000) and
then incubating grids with the secondary gold-labeled
anti-mouse-conjugated antibody (1:100) (Sigma, 30 nm
gold particles) followed by staining with 2% uranyl ace-
tate.
Immunisation of New Zealand white rabbits
Concentrated A. thaliana and N. tabacum protein extracts
(500 μl) were mixed 1:1 (v/v) with Freund's incomplete
adjuvant and injected into New Zealand white rabbits (3
subcutaneous and 1 intramuscular site) on days 1, 28 and
56. Serum collected on days 1, 15, 28, 42, 56 and 70 was
analysed by ELISA (1:20 dilution) against insect cell-
derived HPV-11 L1 and HPV-11 L1 NLS- VLPs coated onto
plates at a concentration of 0.4 μg/100 μl.
Pseudovirion neutralisation experiments
HPV-11 L1 pseudovirions were generated according to the
protocol described by Pastrana et al. [33] with plasmids
obtained from John Schiller (Laboratory of Cellular
Oncology, National Cancer Institute, Bethesda, MD). Sera
from inoculated rabbits collected on Day 56 as well as the
pre-inoculation sera (Day 1) were evaluated for their
capability to neutralise the HPV-11 L1 pseudovirions in
vitro. Threefold dilutions of all pre- and post-inoculation
sera ranging from 1:50 to 1:12,150 were prepared. Sera
were incubated with HPV-11 pseudovirions and the
resulting secreted alkaline phosphatase (SEAP) content
was determined by application of the Great ESCAPE SEAP
chemiluminescence kit (BD Clontech) according to the
manufacturer's instructions.
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